Advarra's single sign-on for sites
At most major conferences, there is usually a topic or buzzword that everyone talks about - and at this year’s SCOPE held in Orlando this week, it was no different.
Source: outsourcing-pharma.com
📰 Clinical Development News
Page 38 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
MENLO PARK, Calif., Feb. 15, 2024 -- Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic,...
Menlo Park United States Josephk Belanoff Clinical Development Drug Administration Development Officer
Source: marketscreener.com
Corcept Therapeutics Announces Fourth Quarter and Full-Year
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
United States Menlo Park Josephk Belanoff American Diabetes Association University Of Chicago Drug Administration
Source: globenewswire.com
Ecobat Hires CEO, First United Bank Names CFO, and Weber Shandwick Selects Dallas Market Leader
Plus, Commerce Bank names new market president, Weitzman promotes two brokerage execs, and more.
New Mexico United States Southern Methodist University Fort Worth University Of Texas University Of Southern California
Source: dmagazine.com
New data from Japan shows early resolution of common Covid-19 symptoms
Japanese pharmaceutical company Shionogi has announced the first peer-reviewed publication of its phase 3 study investigating ensitrelvir to treat patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam.
Takeki Uehara Yohei Doi Ministry Of Health Fujita Health University World Health Organization Drug Administration
Source: outsourcing-pharma.com
First treatment for Friedreich's ataxia in Europe granted approval
Biogen Inc. has taken a step closer to bringing its ‘groundbreaking treatment’ to patients with a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder.
Sylvia Boesch Priya Singhal Rare Movement Disorders Innsbruck Department Of Neurology European Union Friedreich Ataxia Research Alliance
Source: outsourcing-pharma.com
Pharmacies in crisis need Charac's digital help
With independent pharmacies now facing significant challenges, healthcare SaaS provider Charac was pleased to announce more investment so it can accelerate a digitization drive.
Source: outsourcing-pharma.com
Phesi celebrates 100 million global patient data milestone
Phesi’s artificial intelligence (AI) driven platform, Trial Accelerator, has reached a milestone and now contains global data from more than 100 million patients.
Jonathan Peachey Gen Li Japanese Patent Office For Phesi Trial Accelerator Digital Patient Profile Refractory Follicular Lymphoma
Source: outsourcing-pharma.com
J&J: applies to the EMA for a new indication for Rybrevant -February 09, 2024 at 06:09 am EST
The Janssen pharmaceutical companies of Johnson & Johnson announce that they have applied to the European Medicines Agency for an extension of the indication for Rybrevant . The idea is to obtain...
Kiran Patel Clinical Development Janssen Research Development European Medicines Agency Vice President Solid Tumors
Source: marketscreener.com
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled...
Source: lelezard.com